ea hy 926  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC ea hy 926
    4-oxoDHA augments Nrf2-HO-1 pathways and anti-inflammatory properties in endothelial cells. ( a ) Pathway analysis of RNA-sequence data from the control (N/C) and 4-oxoDHA treated (4-oxoDHA) HUVECs. ( b ) HUVECs were treated with DHA (10 µM), 4-HDHA (0.1–10 µM), and 4-oxoDHA (0.1–10 µM) for 6 h at 37 °C. Whole-cell lysates were processed for western blot analysis to determine heme oxygenase-1 (HO-1) expression. β-actin was employed as the internal standard. Data are expressed as fold induction of HO-1 compared to control, mean ± s.e. (n = 3). ****Indicates p < 0.0001. ( c ) Endothelial cell line (EA.hy 926) was treated with DHA (1 µM), 4-HDHA (0.01–1 µM), and 4-oxoDHA (0.01–1 µM) for 6 h at 37 °C. Whole-cell lysates were processed for western blot analysis to determine HO-1 expression. β-actin was used as the internal standard. Data are expressed as fold induction of HO-1 compared to control, mean ± s.e. (n = 5). **Indicates p < 0.01. ( d ) HUVECs were treated with 10 µM of DHA, 4-HDHA, and 4-oxoDHA for 2 h at 37 °C. Nuclear fractions were processed for western blot analysis to determine Nrf2 expression. PCNA was used as the internal standard. Data are expressed as fold induction of Nrf2 compared to control (N/C), mean ± s.e. (n = 3) **,***Indicate p < 0.01, p < 0.001. ( e ) EA.hy 926 cells were treated with 1 µM of DHA, 4-HDHA, and 4-oxoDHA for 1 h, followed by stimulation of H 2 O 2 (500 µM) for 2 h at 37 °C. After incubation, endothelial permeability was investigated with FITC-labeled dextran (MW: 10,000). Data are expressed as percent reduction compared to control, mean ± s.e. (n = 3–4). **Indicates p < 0.01. ( f,g ) HUVECs were treated with 10 µM DHA or 4-oxoDHA after stimulation with Kdo2 (0.5 µg/mL). ICAM-1 ( f ) and E-selectin ( g ) mRNA were analyzed using real-time RT-PCR. Data are expressed as fold change compared to control, mean ± s.e. (n = 7). *,**Indicate p < 0.05, p < 0.01.
    Ea Hy 926, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ea hy 926/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    ea hy 926 - by Bioz Stars, 2024-04
    86/100 stars

    Images

    1) Product Images from "Stress-induced stenotic vascular remodeling via reduction of plasma omega-3 fatty acid metabolite 4-oxoDHA by noradrenaline"

    Article Title: Stress-induced stenotic vascular remodeling via reduction of plasma omega-3 fatty acid metabolite 4-oxoDHA by noradrenaline

    Journal: Scientific Reports

    doi: 10.1038/s41598-024-54867-3

    4-oxoDHA augments Nrf2-HO-1 pathways and anti-inflammatory properties in endothelial cells. ( a ) Pathway analysis of RNA-sequence data from the control (N/C) and 4-oxoDHA treated (4-oxoDHA) HUVECs. ( b ) HUVECs were treated with DHA (10 µM), 4-HDHA (0.1–10 µM), and 4-oxoDHA (0.1–10 µM) for 6 h at 37 °C. Whole-cell lysates were processed for western blot analysis to determine heme oxygenase-1 (HO-1) expression. β-actin was employed as the internal standard. Data are expressed as fold induction of HO-1 compared to control, mean ± s.e. (n = 3). ****Indicates p < 0.0001. ( c ) Endothelial cell line (EA.hy 926) was treated with DHA (1 µM), 4-HDHA (0.01–1 µM), and 4-oxoDHA (0.01–1 µM) for 6 h at 37 °C. Whole-cell lysates were processed for western blot analysis to determine HO-1 expression. β-actin was used as the internal standard. Data are expressed as fold induction of HO-1 compared to control, mean ± s.e. (n = 5). **Indicates p < 0.01. ( d ) HUVECs were treated with 10 µM of DHA, 4-HDHA, and 4-oxoDHA for 2 h at 37 °C. Nuclear fractions were processed for western blot analysis to determine Nrf2 expression. PCNA was used as the internal standard. Data are expressed as fold induction of Nrf2 compared to control (N/C), mean ± s.e. (n = 3) **,***Indicate p < 0.01, p < 0.001. ( e ) EA.hy 926 cells were treated with 1 µM of DHA, 4-HDHA, and 4-oxoDHA for 1 h, followed by stimulation of H 2 O 2 (500 µM) for 2 h at 37 °C. After incubation, endothelial permeability was investigated with FITC-labeled dextran (MW: 10,000). Data are expressed as percent reduction compared to control, mean ± s.e. (n = 3–4). **Indicates p < 0.01. ( f,g ) HUVECs were treated with 10 µM DHA or 4-oxoDHA after stimulation with Kdo2 (0.5 µg/mL). ICAM-1 ( f ) and E-selectin ( g ) mRNA were analyzed using real-time RT-PCR. Data are expressed as fold change compared to control, mean ± s.e. (n = 7). *,**Indicate p < 0.05, p < 0.01.
    Figure Legend Snippet: 4-oxoDHA augments Nrf2-HO-1 pathways and anti-inflammatory properties in endothelial cells. ( a ) Pathway analysis of RNA-sequence data from the control (N/C) and 4-oxoDHA treated (4-oxoDHA) HUVECs. ( b ) HUVECs were treated with DHA (10 µM), 4-HDHA (0.1–10 µM), and 4-oxoDHA (0.1–10 µM) for 6 h at 37 °C. Whole-cell lysates were processed for western blot analysis to determine heme oxygenase-1 (HO-1) expression. β-actin was employed as the internal standard. Data are expressed as fold induction of HO-1 compared to control, mean ± s.e. (n = 3). ****Indicates p < 0.0001. ( c ) Endothelial cell line (EA.hy 926) was treated with DHA (1 µM), 4-HDHA (0.01–1 µM), and 4-oxoDHA (0.01–1 µM) for 6 h at 37 °C. Whole-cell lysates were processed for western blot analysis to determine HO-1 expression. β-actin was used as the internal standard. Data are expressed as fold induction of HO-1 compared to control, mean ± s.e. (n = 5). **Indicates p < 0.01. ( d ) HUVECs were treated with 10 µM of DHA, 4-HDHA, and 4-oxoDHA for 2 h at 37 °C. Nuclear fractions were processed for western blot analysis to determine Nrf2 expression. PCNA was used as the internal standard. Data are expressed as fold induction of Nrf2 compared to control (N/C), mean ± s.e. (n = 3) **,***Indicate p < 0.01, p < 0.001. ( e ) EA.hy 926 cells were treated with 1 µM of DHA, 4-HDHA, and 4-oxoDHA for 1 h, followed by stimulation of H 2 O 2 (500 µM) for 2 h at 37 °C. After incubation, endothelial permeability was investigated with FITC-labeled dextran (MW: 10,000). Data are expressed as percent reduction compared to control, mean ± s.e. (n = 3–4). **Indicates p < 0.01. ( f,g ) HUVECs were treated with 10 µM DHA or 4-oxoDHA after stimulation with Kdo2 (0.5 µg/mL). ICAM-1 ( f ) and E-selectin ( g ) mRNA were analyzed using real-time RT-PCR. Data are expressed as fold change compared to control, mean ± s.e. (n = 7). *,**Indicate p < 0.05, p < 0.01.

    Techniques Used: Sequencing, Western Blot, Expressing, Incubation, Permeability, Labeling, Quantitative RT-PCR

    ea hy 926  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC ea hy 926
    (a) Pathway analysis of RNA-sequence data from the control (N/C) and 4-oxoDHA treated (4-oxoDHA) HUVECs. (b) HUVECs were treated with DHA (10 µM), 4-HDHA (0.1–10 µM), and 4-oxoDHA (0.1–10 µM) for 6h at 37°C. Whole-cell lysates were processed for western blot analysis to determine heme oxygenase-1 (HO-1) expression. β-actin was employed as the internal standard. Data are expressed as fold induction of HO-1 compared to control, mean±s.e. (n=3). **** indicates p<0.0001. (c) Endothelial cell line (EA.hy 926) was treated with DHA (1 µM), 4-HDHA (0.01–1 µM), and 4-oxoDHA (0.01–1 µM) for 6h at 37°C. Whole-cell lysates were processed for western blot analysis to determine HO-1 expression. β-actin was used as the internal standard. Data are expressed as fold induction of HO-1 compared to control, mean±s.e. (n=5). ** indicates p<0.01. (d) HUVECs were treated with 10 µM of DHA, 4-HDHA, and 4-oxoDHA for 2h at 37°C. Nuclear fractions were processed for western blot analysis to determine Nrf2 expression. PCNA was used as the internal standard. Data are expressed as fold induction of Nrf2 compared to control (N/C), mean±s.e. (n=3) **, *** indicate p<0.01, p<0.001. (e) EA.hy 926 cells were treated with 1 µM of DHA, 4-HDHA, and 4-oxoDHA for 1h, followed by stimulation of H 2 O 2 (500 µM) for 2h at 37°C. After incubation, endothelial permeability was investigated with FITC-labeled dextran (MW: 10,000). Data are expressed as percent reduction compared to control, mean±s.e. (n=3–4). ** indicates p<0.01. (f, g) HUVECs were treated with 10 µM DHA or 4-oxoDHA after stimulation with Kdo2 (0.5 µg/mL). ICAM-1 (f) and E-selectin (g) mRNA were analyzed using real-time RT-PCR. Data are expressed as fold change compared to control, mean±s.e. (n=7). *, ** indicate p<0.05, p<0.01.
    Ea Hy 926, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ea hy 926/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    ea hy 926 - by Bioz Stars, 2024-04
    86/100 stars

    Images

    1) Product Images from "Stress-induced vascular remodeling: novel insight into the role of omega-3 fatty acid metabolite, 4-oxoDHA"

    Article Title: Stress-induced vascular remodeling: novel insight into the role of omega-3 fatty acid metabolite, 4-oxoDHA

    Journal: bioRxiv

    doi: 10.1101/2023.07.25.550603

    (a) Pathway analysis of RNA-sequence data from the control (N/C) and 4-oxoDHA treated (4-oxoDHA) HUVECs. (b) HUVECs were treated with DHA (10 µM), 4-HDHA (0.1–10 µM), and 4-oxoDHA (0.1–10 µM) for 6h at 37°C. Whole-cell lysates were processed for western blot analysis to determine heme oxygenase-1 (HO-1) expression. β-actin was employed as the internal standard. Data are expressed as fold induction of HO-1 compared to control, mean±s.e. (n=3). **** indicates p<0.0001. (c) Endothelial cell line (EA.hy 926) was treated with DHA (1 µM), 4-HDHA (0.01–1 µM), and 4-oxoDHA (0.01–1 µM) for 6h at 37°C. Whole-cell lysates were processed for western blot analysis to determine HO-1 expression. β-actin was used as the internal standard. Data are expressed as fold induction of HO-1 compared to control, mean±s.e. (n=5). ** indicates p<0.01. (d) HUVECs were treated with 10 µM of DHA, 4-HDHA, and 4-oxoDHA for 2h at 37°C. Nuclear fractions were processed for western blot analysis to determine Nrf2 expression. PCNA was used as the internal standard. Data are expressed as fold induction of Nrf2 compared to control (N/C), mean±s.e. (n=3) **, *** indicate p<0.01, p<0.001. (e) EA.hy 926 cells were treated with 1 µM of DHA, 4-HDHA, and 4-oxoDHA for 1h, followed by stimulation of H 2 O 2 (500 µM) for 2h at 37°C. After incubation, endothelial permeability was investigated with FITC-labeled dextran (MW: 10,000). Data are expressed as percent reduction compared to control, mean±s.e. (n=3–4). ** indicates p<0.01. (f, g) HUVECs were treated with 10 µM DHA or 4-oxoDHA after stimulation with Kdo2 (0.5 µg/mL). ICAM-1 (f) and E-selectin (g) mRNA were analyzed using real-time RT-PCR. Data are expressed as fold change compared to control, mean±s.e. (n=7). *, ** indicate p<0.05, p<0.01.
    Figure Legend Snippet: (a) Pathway analysis of RNA-sequence data from the control (N/C) and 4-oxoDHA treated (4-oxoDHA) HUVECs. (b) HUVECs were treated with DHA (10 µM), 4-HDHA (0.1–10 µM), and 4-oxoDHA (0.1–10 µM) for 6h at 37°C. Whole-cell lysates were processed for western blot analysis to determine heme oxygenase-1 (HO-1) expression. β-actin was employed as the internal standard. Data are expressed as fold induction of HO-1 compared to control, mean±s.e. (n=3). **** indicates p<0.0001. (c) Endothelial cell line (EA.hy 926) was treated with DHA (1 µM), 4-HDHA (0.01–1 µM), and 4-oxoDHA (0.01–1 µM) for 6h at 37°C. Whole-cell lysates were processed for western blot analysis to determine HO-1 expression. β-actin was used as the internal standard. Data are expressed as fold induction of HO-1 compared to control, mean±s.e. (n=5). ** indicates p<0.01. (d) HUVECs were treated with 10 µM of DHA, 4-HDHA, and 4-oxoDHA for 2h at 37°C. Nuclear fractions were processed for western blot analysis to determine Nrf2 expression. PCNA was used as the internal standard. Data are expressed as fold induction of Nrf2 compared to control (N/C), mean±s.e. (n=3) **, *** indicate p<0.01, p<0.001. (e) EA.hy 926 cells were treated with 1 µM of DHA, 4-HDHA, and 4-oxoDHA for 1h, followed by stimulation of H 2 O 2 (500 µM) for 2h at 37°C. After incubation, endothelial permeability was investigated with FITC-labeled dextran (MW: 10,000). Data are expressed as percent reduction compared to control, mean±s.e. (n=3–4). ** indicates p<0.01. (f, g) HUVECs were treated with 10 µM DHA or 4-oxoDHA after stimulation with Kdo2 (0.5 µg/mL). ICAM-1 (f) and E-selectin (g) mRNA were analyzed using real-time RT-PCR. Data are expressed as fold change compared to control, mean±s.e. (n=7). *, ** indicate p<0.05, p<0.01.

    Techniques Used: Sequencing, Western Blot, Expressing, Incubation, Permeability, Labeling, Quantitative RT-PCR